RTW Investments LP Has $208.13 Million Holdings in Insmed Incorporated (NASDAQ:INSM)

RTW Investments LP lowered its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,014,558 shares of the biopharmaceutical company's stock after selling 257,450 shares during the quarter. Insmed makes up 3.1% of RTW Investments LP's investment portfolio, making the stock its 11th largest holding. RTW Investments LP owned about 1.69% of Insmed worth $208,125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. National Bank of Canada FI increased its stake in Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 147 shares in the last quarter. Abel Hall LLC increased its stake in Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after purchasing an additional 151 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares in the last quarter. M&T Bank Corp grew its stake in Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after acquiring an additional 166 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 183 shares during the period.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 1,799 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $67.53, for a total value of $121,486.47. Following the completion of the sale, the insider now directly owns 84,797 shares in the company, valued at approximately $5,726,341.41. The trade was a 2.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 18,750 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $27,079,091.58. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 162,283 shares of company stock worth $11,827,910. 3.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on INSM shares. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Guggenheim reiterated a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. UBS Group dropped their target price on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Bank of America upped their target price on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $94.63.

Insmed Stock Down 0.4%

NASDAQ INSM traded down $0.24 during trading on Monday, hitting $67.88. 1,334,593 shares of the company traded hands, compared to its average volume of 2,325,724. The business has a fifty day simple moving average of $71.45 and a 200 day simple moving average of $73.16. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $12.36 billion, a P/E ratio of -12.14 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same quarter last year, the firm posted ($1.06) earnings per share. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.